NEW YORK – Clinical stage biotechnology company Tiziana Life Sciences said on Wednesday it plans to spin off its StemPrintER asset into a separate and independently listed public company called Accustem Sciences.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.